Skip to main content

Table 1 Characteristics at cART initiation

From: Prevalence and effect of pre-treatment drug resistance on the virological response to antiretroviral treatment initiated in HIV-infected children – a EuroCoord-CHAIN-EPPICC joint project

Characteristics   Number Percent
Sex Female 246 51.7
Age years median (IQR)   6 (2 ; 10)
Age (years) <2 115 24.2
  2–5 113 23.7
  6–12 197 41.4
  13–17 51 10.7
Region of origin Africa 113 23.7
  Asia 194 40.8
  Europe 118 24.8
  Other/unknown 51 10.7
Transmission risk group Vertical 419 88.0
  IDU 1 0.2
  Heterosexual 12 2.5
  Other/unknown 44 9.2
Previous AIDS diagnosis Yes 99 20.8
  No 375 78.8
  Unknown 2 0.4
Pretreatment CD4 cell count (/mm3) median (IQR)*   364 (294; 422)
Pretreatment CD4 cell count (/mm3)* <200 156 37.9
  ≥200 and < 350 77 19.2
  ≥350 and <500 41 10.0
  ≥500 138 33.5
Pretreatment HIV RNA (log10 copies/mL) median (IQR)**   5.2 (4.7; 5.7)
Pretreatment HIV RNA (log10 copies/mL)** <4 36 8
  ≥4 and <5 137 30.5
  ≥5 and <6 214 47.7
  >6 62 13.8
HIV subtype Non B 382 80.3
  B 63 13.2
  Unknown 31 6.5
Year of cART start 1998–1999 105 22.1
  2000–2002 57 12.0
  2003–2004 112 23.5
  2005–2006 149 31.3
  2007–2008 53 11.1
Antiretroviral drug combination NNRTI plus ≥ 2NRTIsa 273 57.4
  Unboosted PI plus ≥ 2NRTIsb 139 29.2
  Boosted PI plus ≥ 2NRTIsc 43 9.0
  Otherd 21 4.4
  1. aIncludes 232 who received 2 NRTIs and 41 who received 3 NRTIs. Overall, 184 were on efavirenz and 89 on nevirapine
  2. bIncludes 136 who received 2 NRTIs and 1 each who received 3, 4, and 5 NRTIs. 131 were on nelfinavir, 3 on indinavir, and 2 on ritonavir
  3. cIncludes 37 who received 2 NRTIs, 5 who received 3 NRTIs, and 1 who received 4 NRTIs. 32 were on lopinavir/ritonavir, 5 on fosamprenavir/ritonavir, 4 on indinavir/ritonavir, and one each on atazanavir or saquinavir with ritonavir
  4. dIncludes 10 who received (1 NNRTI plus ≥ 2NRTIs plus 1 PI or 1 boosted PI), 5 who received (2NNRTIs plus ≥ 2NRTIs), 4 who received (≥1 NRTI plus 2 PI/boosted PI), 1 who received (1 NRTI plus boosted PI plus integrase inhibitor plus fusion inhibitor), and 1 who received (1 NRTI plus 1 boosted PI plus 1 fusion inhibitor). *CD4 cell count measurements at cART initiation were available for 412 children. **Viral load measurements at cART initiation were available for 449 children